{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:13:00Z","timestamp":1793167980014,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Scientific Research, Tiaf University","award":["project #1\u2013439\u20136099"],"award-info":[{"award-number":["project #1\u2013439\u20136099"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperuricemia is an abnormal increase in uric acid levels in the blood. It is the cause of gout that manifested by inflammatory arthritis and painful disable. Therefore, current study evaluated the potential ameliorative impact of Lesinurad and Allopurinol on the kidneys of hyperuricemic mice at the biochemical, molecular and cellular levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Lesinurad and allopurinol alone or in combination were orally administered to hyperuricemic and control mice for seven consecutive days. Levels of uric acid and blood urea nitrogen, along with antioxidants and inflammatory cytokines (IL-1\u03b2 and TNF-\u03b1) were measured in the serum. The mRNA expression of mouse urate anion transporter-1, glucose transporter 9, organic anion transporters, in renal tissues were examined using quantitative real time PCR. Simultaneously, the immunoreactivity of transforming growth factor-beta 1 was examined immunohistochemically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lesinurad and allopurinol administration resulted in significant decrease in serum levels of uric acid, blood urea nitrogen, xanthine oxidase activity, catalase, glutathione peroxidase and inflammatory cytokines (IL-1\u03b2 and TNF-\u03b1) reported in hyperuricemic mice. Both partially reversed oxonate-induced alterations in renal mURAT-1, mGLUT-9, mOAT-1 and mOAT-3 expressions, as well as alterations in the immunoreactivity of TGF- \u03b21, resulting in the increase of renal uric acid secretion and excretion. The combined administration of lesinurad and ALP restored all altered parameters in a synergistic manner, improving renal function in the hyperuricemic mouse model employed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed synergistic ameliorative hypouricemic impact of both lesinurad and allopurinol in the treatment of hyperuricemia in mice at the biochemical, molecular and cellular levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-020-0386-7","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T12:02:50Z","timestamp":1581336170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study"],"prefix":"10.1186","volume":"21","author":[{"given":"Youssef Saeed","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mohamed","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-7123","authenticated-orcid":false,"given":"Mohamed Abdo","family":"Nassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"386_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000355405","volume":"3","author":"K Chaudhary","year":"2013","unstructured":"Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3:208\u201320.","journal-title":"Cardiorenal Med"},{"key":"386_CR2","doi-asserted-by":"publisher","first-page":"e38123","DOI":"10.1371\/journal.pone.0038123","volume":"7","author":"L Zgaga","year":"2012","unstructured":"Zgaga L, Theodoratou E, Kyle J, Farrington SM, Agakov F, Tenesa A, Walker M, McNeill G, Wright AF, Rudan I, et al. The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One. 2012;7:e38123.","journal-title":"PLoS One"},{"key":"386_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","volume":"9","author":"KL Rock","year":"2013","unstructured":"Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13\u201323.","journal-title":"Nat Rev Rheumatol"},{"key":"386_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","volume":"61","author":"DI Jalal","year":"2013","unstructured":"Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134\u201346.","journal-title":"Am J Kidney Dis"},{"key":"386_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1758-5996-4-12","volume":"4","author":"EP de Oliveira","year":"2012","unstructured":"de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndrome. 2012;4:12.","journal-title":"Diabetol Metab Syndrome"},{"key":"386_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/PPA.S97927","volume":"11","author":"T Aung","year":"2017","unstructured":"Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Preference Adherence. 2017;11:795\u2013800.","journal-title":"Patient Preference Adherence"},{"key":"386_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.","journal-title":"BMC Nephrol"},{"key":"386_CR8","doi-asserted-by":"publisher","first-page":"e8525","DOI":"10.1136\/bmj.e8525","volume":"346","author":"F Lapi","year":"2013","unstructured":"Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.","journal-title":"BMJ"},{"key":"386_CR9","first-page":"68","volume":"47","author":"JN Zhu","year":"2016","unstructured":"Zhu JN, Qi XY, Tan Y, Lyu XH. Dietary Factors Associated with Hyperuricemia and Glycolipid Metabolism Disorder in Middle-aged and Elderly People. Sichuan da xue xue bao Yi xue ban. 2016;47:68\u201372.","journal-title":"Sichuan da xue xue bao Yi xue ban"},{"key":"386_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093\u2013103.","journal-title":"N Engl J Med"},{"key":"386_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmed.2018.00160","volume":"5","author":"CL Benn","year":"2018","unstructured":"Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C. Physiology of Hyperuricemia and Urate-lowering treatments. Front Med. 2018;5:160.","journal-title":"Front Med"},{"key":"386_CR12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1189\/jlb.70.4.659","volume":"70","author":"P Desaulniers","year":"2001","unstructured":"Desaulniers P, Fernandes M, Gilbert C, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation. VII Involvement of Syk in the responses to monosodium urate crystals. J Leukocyte Biol. 2001;70:659\u201368.","journal-title":"J Leukocyte Biol"},{"key":"386_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6:30\u20138.","journal-title":"Nat Rev Rheumatol"},{"key":"386_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbrc.2014.08.068","volume":"452","author":"C Knake","year":"2014","unstructured":"Knake C, Stamp L, Bahn A. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun. 2014;452:157\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"386_CR15","doi-asserted-by":"publisher","first-page":"212581","DOI":"10.7573\/dic.212581","volume":"8","author":"F Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz F, Jansen T, Tausche AK, Juarez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019;8:212581.","journal-title":"Drugs Context"},{"key":"386_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447\u201352.","journal-title":"Nature"},{"issue":"6","key":"386_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/0897190017734427","volume":"31","author":"Emily Huneycutt","year":"2017","unstructured":"Huneycutt E, Board C, Clements JN. Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for Hyperuricemia associated with gout. J Pharm Pract. 2017. https:\/\/doi.org\/10.1177\/0897190017734427.","journal-title":"Journal of Pharmacy Practice"},{"key":"386_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-016-0550-y","volume":"76","author":"SM Hoy","year":"2016","unstructured":"Hoy SM. Lesinurad: first global approval. Drugs. 2016;76:509\u201316.","journal-title":"Drugs"},{"key":"386_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00394-011-0243-y","volume":"51","author":"QH Hu","year":"2012","unstructured":"Hu QH, Zhang X, Wang X, Jiao RQ, Kong LD. Quercetin regulates organic ion transporter and uromodulin expression and improves renal function in hyperuricemic mice. Eur J Nutr. 2012;51:593\u2013606.","journal-title":"Eur J Nutr"},{"key":"386_CR20","doi-asserted-by":"publisher","first-page":"852954","DOI":"10.1155\/2014\/852954","volume":"2014","author":"L Billiet","year":"2014","unstructured":"Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014;2014:852954.","journal-title":"ISRN Rheumatol"},{"key":"386_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.pharep.2017.04.022","volume":"69","author":"T Wu","year":"2017","unstructured":"Wu T, Chen J, Dong S, Li H, Cao Y, Tian Y, Fu W, Zhou P, Xi B, Pang J. Identification and characterization of a potent and selective inhibitor of human urate transporter 1. Pharmacol Rep. 2017;69:1103\u201312.","journal-title":"Pharmacol Rep"},{"key":"386_CR22","first-page":"811","volume":"10","author":"F Haidari","year":"2011","unstructured":"Haidari F, Keshavarz SA, Mohammad Shahi M, Mahboob SA, Rashidi MR. Effects of parsley (Petroselinum crispum) and its Flavonol constituents, Kaempferol and Quercetin, on serum uric acid levels, biomarkers of oxidative stress and liver xanthine Oxidoreductase Aactivity inOxonate-induced Hyperuricemic rats. Iran J Pharmaceutical Res. 2011;10:811\u20139.","journal-title":"Iran J Pharmaceutical Res"},{"key":"386_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12011-015-0280-0","volume":"167","author":"MM Soliman","year":"2015","unstructured":"Soliman MM, Baiomy AA, Yassin MH. Molecular and Histopathological study on the ameliorative effects of Curcumin against Lead acetate-induced hepatotoxicity and Nephrototoxicity in Wistar rats. Biol Trace Elem Res. 2015;167:91\u2013102.","journal-title":"Biol Trace Elem Res"},{"key":"386_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12906-017-1833-x","volume":"17","author":"DY Saad","year":"2017","unstructured":"Saad DY, Soliman MM, Baiomy AA, Yassin MH, El-Sawy HB. Effects of Karela (bitter melon; Momordica charantia) on genes of lipids and carbohydrates metabolism in experimental hypercholesterolemia: biochemical, molecular and histopathological study. BMC Complement Altern Med. 2017;17:319.","journal-title":"BMC Complement Altern Med"},{"key":"386_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000443769","volume":"3","author":"M Kuwabara","year":"2016","unstructured":"Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel). 2016;3:242\u201352.","journal-title":"Pulse (Basel)"},{"issue":"Suppl 1","key":"386_CR26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G Nuki","year":"2006","unstructured":"Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(Suppl 1):S1.","journal-title":"Arthritis Res Ther"},{"key":"386_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejphar.2014.11.035","volume":"747","author":"MX Wang","year":"2015","unstructured":"Wang MX, Liu YL, Yang Y, Zhang DM, Kong LD. Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Eur J Pharmacol. 2015;747:59\u201370.","journal-title":"Eur J Pharmacol"},{"key":"386_CR28","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","volume":"138","author":"FS Di Giovine","year":"1987","unstructured":"Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol (Baltimore). 1987;138:3213\u20138.","journal-title":"J Immunol (Baltimore)"},{"key":"386_CR29","first-page":"82","volume":"64","author":"R Terkeltaub","year":"2006","unstructured":"Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Joint Dis. 2006;64:82\u20136.","journal-title":"Bull NYU Hosp Joint Dis"},{"key":"386_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0014-5793(01)02237-2","volume":"492","author":"M Zamocky","year":"2001","unstructured":"Zamocky M, Regelsberger G, Jakopitsch C, Obinger C. The molecular peculiarities of catalase-peroxidases. FEBS Lett. 2001;492:177\u201382.","journal-title":"FEBS Lett"},{"key":"386_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exger.2016.08.012","volume":"84","author":"J Selvaratnam","year":"2016","unstructured":"Selvaratnam J, Robaire B. Overexpression of catalase in mice reduces age-related oxidative stress and maintains sperm production. Exp Gerontol. 2016;84:12\u201320.","journal-title":"Exp Gerontol"},{"key":"386_CR32","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s10067-015-2933-y","volume":"34","author":"Y Zamudio-Cuevas","year":"2015","unstructured":"Zamudio-Cuevas Y, Hernandez-Diaz C, Pineda C, Reginato AM, Cerna-Cortes JF, Ventura-Rios L, Lopez-Reyes A. Molecular basis of oxidative stress in gouty arthropathy. Clin Rheumatol. 2015;34:1667\u201372.","journal-title":"Clin Rheumatol"},{"key":"386_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","volume":"24","author":"EU Smith","year":"2010","unstructured":"Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24:811\u201327.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"386_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011;63:102\u201310.","journal-title":"Arthritis Care Res"},{"key":"386_CR35","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53:2167\u201374.","journal-title":"Rheumatology (Oxford)"},{"key":"386_CR36","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2147\/DDDT.S85193","volume":"9","author":"Z Shen","year":"2015","unstructured":"Shen Z, Rowlings C, Kerr B, Hingorani V, Manhard K, Quart B, Yeh LT, Storgard C. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Design Dev Ther. 2015;9:3423\u201334.","journal-title":"Drug Design Dev Ther"},{"key":"386_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol (Hoboken). 2017;69:203\u201312.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"386_CR38","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75:1074\u201380.","journal-title":"Ann Rheum Dis"},{"key":"386_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","volume":"18","author":"JN Miner","year":"2016","unstructured":"Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214.","journal-title":"Arthritis Res Ther"},{"key":"386_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/17425255.2012.667401","volume":"8","author":"EI Lepist","year":"2012","unstructured":"Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol. 2012;8:433\u201348.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"386_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12565-016-0369-3","volume":"92","author":"N Otani","year":"2017","unstructured":"Otani N, Ouchi M, Hayashi K, Jutabha P, Anzai N. Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. Anat Sci Int. 2017;92:200\u20136.","journal-title":"Anat Sci Int"},{"key":"386_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40261-016-0386-y","volume":"36","author":"Z Shen","year":"2016","unstructured":"Shen Z, Yeh LT, Wallach K, Zhu N, Kerr B, Gillen M. In vitro and in vivo interaction studies between Lesinurad, a selective Urate reabsorption inhibitor, and major liver or kidney transporters. Clinical Drug Investig. 2016;36:443\u201352.","journal-title":"Clinical Drug Investig"},{"key":"386_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437\u201342.","journal-title":"Nat Genet"},{"key":"386_CR44","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0006-2952(03)00466-0","volume":"66","author":"Y Habu","year":"2003","unstructured":"Habu Y, Yano I, Takeuchi A, Saito H, Okuda M, Fukatsu A, Inui K. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem Pharmacol. 2003;66:1107\u201314.","journal-title":"Biochem Pharmacol"},{"key":"386_CR45","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1172\/JCI40124","volume":"120","author":"H Kono","year":"2010","unstructured":"Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 2010;120:1939\u201349.","journal-title":"J Clin Invest"},{"key":"386_CR46","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12882-017-0736-x","volume":"18","author":"MM Romi","year":"2017","unstructured":"Romi MM, Arfian N, Tranggono U, Setyaningsih WAW, Sari DCR. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. BMC Nephrol. 2017;18:326.","journal-title":"BMC Nephrol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-0386-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0386-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:33:43Z","timestamp":1722411223000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-0386-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-0386-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17096\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17096\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17096\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable on this section.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}